PentaLyte decreases lung injury after aortic occlusion-reperfusion.
Lung injury often occurs after hepatoenteric ischemia, with xanthine oxidase (XO, an oxidant-generating enzyme), released from reperfusing liver and intestines, mediating a significant component of this injury. Since pentastarch administration decreases intestinal reperfusion injury, we determined whether resuscitation with PentaLyte (a pentastarch-containing solution) would decrease hepatoenteric reperfusion injury, xanthine oxidase release, and concomitant lung injury after aortic occlusion- reperfusion. Aortic occlusion was established in rabbits for 40 min, and was followed by 3 h of reperfusion, during which either PentaLyte or lactated Ringer's solution-based resuscitation was administered. Sham-operated animals served as controls. Hepatoenteric reperfusion injury, as manifested by release of the enzyme aspartate aminotransferase and decreased gastric intramucosal pH, was significantly (p < 0.0167) attenuated by PentaLyte administration after aortic occlusion-reperfusion, as compared with its occurrence in animals given lactated Ringer's solution. The release of XO after aortic occlusion-reperfusion was 4-fold smaller after PentaLyte administration than after resuscitation with lactated Ringer's solution (p < 0.05). Pulmonary injury, as defined by an increase in bronchoalveolar lavage fluid (BALF) protein content and lactate dehydrogenase (LDH) activity, was 4-fold less after PentaLyte administration following aortic occlusion-reperfusion than after administration of lactated Ringer's solution (p < 0.05). We conclude that remote pulmonary injury is significantly decreased by concomitant PentaLyte-mediated reduction of hepatoenteric reperfusion injury and XO release.
Axon
R N
RN
Departments of Anesthesiology and Comparative Medicine, and the Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Baird
M S
MS
Lang
J D
JD
Brix
A E
AE
Nielsen
V G
VG
D000818:Animals; D001013:Aorta, Thoracic / Q000502:physiology; D001219:Aspartate Aminotransferases / Q000097:blood; D001798:Blood Proteins / Q000032:analysis; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D003250:Constriction; D004573:Electrolytes / Q000008:administration & dosage*; D005753:Gastric Mucosa / Q000378:metabolism; D005947:Glucose / Q000008:administration & dosage*; D006863:Hydrogen-Ion Concentration; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D007422:Intestines / Q000098:blood supply*; D007552:Isotonic Solutions / Q000008:administration & dosage; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008099:Liver / Q000098:blood supply*; D008297:Male; D010656:Phenylephrine / Q000008:administration & dosage; D010952:Plasma Substitutes / Q000008:administration & dosage*; D011817:Rabbits; D015427:Reperfusion Injury / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D012128:Respiratory Distress Syndrome / Q000209:etiology / Q000517:prevention & control*; D012151:Resuscitation; D000077325:Ringer's Lactate; D017693:Sodium Bicarbonate / Q000008:administration & dosage; D014969:Xanthine Oxidase / Q000097:blood
D001798:Blood Proteins; D004573:Electrolytes; D006895:Hydroxyethyl Starch Derivatives; D007552:Isotonic Solutions; C112942:PentaLyte; D010952:Plasma Substitutes; D000077325:Ringer's Lactate; D010656:Phenylephrine; D017693:Sodium Bicarbonate; D007770:L-Lactate Dehydrogenase; D014969:Xanthine Oxidase; D001219:Aspartate Aminotransferases; D005947:Glucose